Insmed to Present Data Across Its Respiratory Portfolio, Including Late-Breaking ARIKAYCE® Results from Phase 3b ENCORE Study, at the American Thoracic Society International Conference 2026
Insmed announced it will present six abstracts at the upcoming American Thoracic Society International Conference, highlighted by late-breaking results from the Phase 3b ENCORE study of ARIKAYCE in newly diagnosed Mycobacterium avium complex lung disease. Additional presentations will include post-hoc analyses of BRINSUPRI, pharmacokinetic data for Treprostinil Palmitil Inhalation Powder, and real-world disease burden data.
Key figures
- Drug Name
- ARIKAYCE
- Phase Of Trial
- Phase 3b
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.